# Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns

- URL: https://talkfuse.com/story/ozempic-and-zepbound-users-face-6-rebound-risks-after-stopping-doctor-warns/
- Published: 2026-11-12T13:00:40+00:00
- Updated: 2026-11-12T13:25:04+00:00
- Original publisher: Fox News (publisher lean: Right)
- Original article: https://www.foxnews.com/health/ozempic-zepbound-users-face-6-rebound-risks-stopping-doctor-warns
- Topics: Health, Mental Health, World

## Key points

- Hunger and cravings may return after stopping GLP-1 treatment.
- Trial participants regained much of their lost weight.
- A doctor recommends discussing treatment changes with a physician.

## Summary

Doctors warn that stopping GLP-1 medicines such as Ozempic, Wegovy and Zepbound can bring back appetite and lead to weight regain, as well as reversing some health benefits. The risks matter because obesity and diabetes often need ongoing management, and many patients stop treatment within a year.

The article outlines six potential rebound risks, though the supplied text details only some of them: increased hunger and cravings, weight regain, worsening health markers, loss of cardiovascular protection and loss of muscle mass. In one semaglutide trial extension, participants regained about two-thirds of their lost weight within a year; in a tirzepatide trial, those switched to placebo regained more than half. Side effects, medical concerns and reluctance to take long-term medication can prompt people to stop, so the doctor advises discussing the decision with a physician.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.